Karbis (Candesartan Cilexetil)

Candesartan cilexetil is converted in the body to candesartan, which selectively blocks angiotensin II type 1 (AT1) receptors. This inhibition prevents angiotensin II‑induced vasoconstriction and aldosterone release, resulting in relaxed blood vessels, lower peripheral resistance, and decreased blood pressure.

The appropriate dose of Karbis is determined by the prescribing healthcare professional based on the patient’s clinical condition, response to therapy, and any concomitant medications. Patients should follow the dosage instructions provided by their prescriber.

The safety of candesartan cilexetil in pregnancy and lactation has not been established. It is generally avoided in pregnant or nursing women unless the potential benefit justifies the potential risk, and the decision should be made by a qualified clinician.

To request Karbis, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Karbis belongs to the ARB class, offering blood‑pressure reduction similar to ACE inhibitors but with a lower incidence of cough and angioedema. Compared with calcium‑channel blockers, ARBs act on the renin‑angiotensin system rather than calcium channels, providing an alternative mechanism for patients who need additional control or cannot tolerate other classes.

Karbis should be stored at ambient temperature, preferably below 25 °C, in its original packaging to protect it from moisture and light. Keep the product out of reach of children and do not use it after the expiration date indicated on the label.

Karbis is taken orally, usually once daily, with or without food. The tablet should be swallowed whole with a glass of water and not chewed or crushed unless specifically instructed by a healthcare professional.

Serious adverse events, although uncommon, include angioedema, severe hypotension, acute kidney injury, and marked hyperkalemia. Patients should seek immediate medical attention if they experience swelling of the face or throat, sudden dizziness, fainting, or signs of kidney dysfunction.

Karbis is contraindicated in patients with known hypersensitivity to candesartan or any component of the formulation, in those with severe hepatic impairment, and in individuals who are concurrently using ACE inhibitors or aliskiren (in diabetic patients). Clinical judgment is required for other special populations.